Global Biosimilar and Follow-on Biologics Market Overview: 2019-2027

Biosimilars are defined as a type of biological product that is similar to another drug, which has already been licensed (approved) by the US FDA or European Medicines Agency. The introduction of biosimilars to the market has created new opportunities as well the need for changes in practice within healthcare institutions. The report on the Global Biosimilar and Follow-on Biologics Market gives an estimation of the development of the market based on historical studies and also provides forecasts on the basis of comprehensive research. The report gives a complete market analysis for the forecast period from 2019 to 2027. The market is divided into various segments with an in-depth outlook of the competitors and a listing of the profiled key players. Leading players in the global dipstick urinalysis market includes Zydus Cadila, Dr. Reddy's Laboratories, Emcure Pharmaceuticals, Wockhardt, Roche, and Quintiles. The market size in terms of revenue and volume is calculated and provided for the study period along with the dynamics of the market such as the drivers and the restraints. Global Biosimilar and Follow-on Biologics Market Dynamics Needs and opportunities in developing biosimilar monoclonal antibodies (mAbs) are the major driving factor for the growth of the global market. The rising incidence of cancers and increasing demand for lower-cost biological products create the opportunity for the global biosimilar and follow-on biologics market. Developments in technology and operations for biosimilar drug production are helping to grow this market rapidly in the forecast period. Big brand name drugs losing patent extensions, cuts in healthcare costs across nations, forming of pricing policies by companies in order to access high growth pharmerging markets, good development in pharmacovigilance procedures across the globe are the factors acting as drivers for the growth of the global market. Other factors increasing the demand for biosimilar drugs market are rising disease incidences across the globe and better access to healthcare for all nations. Restraints for the market include constraints in developing and registering biosimilar drugs and the complexity in the manufacturing processes. The Biosimilar and Follow-on Biologics Market has been segmented based on product class, application, and region. By Product Class • Monoclonal Antibodies (Mabs) • Insulin • Erythropoietin (EPO) • Interferons • Growth Hormones • Fertility Hormones Monoclonal antibody technology and bioassay technologies are the most significant technologies used in biosimilar development and validation. Monoclonal Antibodies are the highest revenue-generating biosimilars drug candidate by their high approval rate for commercialization. Mabs are the fastest growing drugs in the biosimilars market. This growth is supplemented by the use of Mabs across a wide range of applications. Recent changes in FDA’s approach to Monoclonal antibodies biosimilars have favored the expansion of the biosimilars and follow-on biologics market. Global Biosimilar and Follow-on Biologics Market Growing research on follow-on Monoclonal Antibodies with sizable research investments by biopharmaceutical companies in the market and the commercialization of biosimilars into routine clinical practice is driving the monoclonal antibodies biologics market in the forecast period. Most of the lucrative products in biosimilars industries are monoclonal antibodies, G-CSF erythropoietin, and peptide. These products are currently commanding the biosimilars market. Companies manufacturing these biosimilars are achieving economies of scale in the market; thus, receiving a cost advantage in a price-sensitive market. Further advancement in technologies would lead to the development of more competent biosimilars, such as Insulin and these biosimilars would outperform the existing biosimilars. Growing awareness and low cost are the factors driving the market growth for monoclonal antibodies biosimilars in the current market. By Application • Blood disorders • Oncology diseases • Growth hormone deficiencies • Others Many of the available biosimilars are indicated for oncology or supportive care indications, with several biosimilars versions of biotherapeutics, approved for use in pharmaceutical markets around the world. Several patents for originator biotherapeutics used in oncology have recently expired or are anticipated to expire in the coming years in the United States and Europe, indicating future growth and continued expansion of biosimilar use in the oncology setting. Oncology pharmacists are well-positioned to act as resources for staff and patient education regarding the safety and efficacy of biosimilars as compared to originator products. Biosimilar products have the potential to improve patient access to important biologic therapies, robust evidence of outcomes for monoclonal antibody biosimilars in treating cancer patients. Biosimilar therapies help to reduce the burden on healthcare stakeholders, which may create by biological cancer treatments. By Region • North America • Europe • Asia-Pacific • MEA & Africa • Latin America Global Biosimilar and Follow-on Biologics Market 1 Europe is expected to command largest market share of XX% by 2027. Rising technological advancements in healthcare and the systematic drug review process will drive the markets from Europe. High patient awareness and regulatory harmonization dominate the biosimilar market in Europe. Increasing funding for the development of biosimilar drugs, availability of high-quality research infrastructure, and strategies developed by drug makers to restrict the entry of new players are also the driving factors for the global market in Europe. Rising disease incidences in these countries are expected to prove favorable for the growth of the biosimilar drug market. A good example of this is Pfizer's acquisition of Hospira, to gain access to the latter’s attractive biosimilars portfolio.

Key Players Operating in Global market includes

• Zydus Cadila • Dr. Reddy's Laboratories • Emcure Pharmaceuticals • Wockhardt • Roche • Quintiles • Gennova • Bayer • AstraZeneca • Hindustan Antibiotic • Takeda • GlaxoSmithKline • Teva • Syngene International • Pfizer • Johnson & Johnson • Ortho Pharmaceutical • Sanofi • Merck KGaA • Samsung BioLogics • Ranbaxy Laboratories • Novartis • Novo Nordisk
Global Biosimilar and Follow-on Biologics Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Biosimilar and Follow-on Biologics Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Biosimilar and Follow-on Biologics Market Analysis and Forecast 6.1. Biosimilar and Follow-on Biologics Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Biosimilar and Follow-on Biologics Market Analysis and Forecast, By Product Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Biosimilar and Follow-on Biologics Market Value Share Analysis, By Product Class 7.4. Biosimilar and Follow-on Biologics Market Size (US$ Mn) Forecast, By Product Class 7.5. Biosimilar and Follow-on Biologics Market Analysis, By Product Class 7.6. Biosimilar and Follow-on Biologics Market Attractiveness Analysis, By Product Class 8. Global Biosimilar and Follow-on Biologics Market Analysis and Forecast, By Application 8.1. Introduction and Definition 8.2. Key Findings 8.3. Biosimilar and Follow-on Biologics Market Value Share Analysis, By Application 8.4. Biosimilar and Follow-on Biologics Market Size (US$ Mn) Forecast, By Application 8.5. Biosimilar and Follow-on Biologics Market Analysis, By Application 8.6. Biosimilar and Follow-on Biologics Market Attractiveness Analysis, By Application 9. Global Biosimilar and Follow-on Biologics Market Analysis, By Region 9.1. Biosimilar and Follow-on Biologics Market Value Share Analysis, By Region 9.2. Biosimilar and Follow-on Biologics Market Size (US$ Mn) Forecast, By Region 9.3. Biosimilar and Follow-on Biologics Market Attractiveness Analysis, By Region 10. North America Biosimilar and Follow-on Biologics Market Analysis 10.1. Key Findings 10.2. North America Biosimilar and Follow-on Biologics Market Overview 10.3. North America Biosimilar and Follow-on Biologics Market Value Share Analysis, By Product Class 10.4. North America Biosimilar and Follow-on Biologics Market Forecast, By Product Class 10.4.1. Monoclonal Antibodies (Mabs) 10.4.2. Insulin 10.4.3. Erythropoietin (EPO) 10.4.4. Interferons 10.4.5. Growth Hormones 10.4.6. Fertility Hormones 10.5. North America Biosimilar and Follow-on Biologics Market Value Share Analysis, By Application 10.6. North America Biosimilar and Follow-on Biologics Market Forecast, By Application 10.6.1. Blood disorders 10.6.2. Oncology diseases 10.6.3. Growth hormone deficiencies 10.6.4. Others 10.7. North America Biosimilar and Follow-on Biologics Market Value Share Analysis, By Country 10.8. North America Biosimilar and Follow-on Biologics Market Forecast, By Country 10.8.1. U.S. 10.8.2. Canada 10.8.3. Mexico 10.9. North America Biosimilar and Follow-on Biologics Market Analysis, By Country 10.10. U.S. Biosimilar and Follow-on Biologics Market Forecast, By Product Class 10.10.1. Monoclonal Antibodies (Mabs) 10.10.2. Insulin 10.10.3. Erythropoietin (EPO) 10.10.4. Interferons 10.10.5. Growth Hormones 10.10.6. Fertility Hormones 10.11. U.S. Biosimilar and Follow-on Biologics Market Forecast, By Application 10.11.1. Blood disorders 10.11.2. Oncology diseases 10.11.3. Growth hormone deficiencies 10.11.4. Others 10.12. Canada Biosimilar and Follow-on Biologics Market Forecast, By Product Class 10.12.1. Monoclonal Antibodies (Mabs) 10.12.2. Insulin 10.12.3. Erythropoietin (EPO) 10.12.4. Interferons 10.12.5. Growth Hormones 10.12.6. Fertility Hormones 10.13. Canada Biosimilar and Follow-on Biologics Market Forecast, By Application 10.13.1. Blood disorders 10.13.2. Oncology diseases 10.13.3. Growth hormone deficiencies 10.13.4. Others 10.14. Mexico Biosimilar and Follow-on Biologics Market Forecast, By Product Class 10.14.1. Monoclonal Antibodies (Mabs) 10.14.2. Insulin 10.14.3. Erythropoietin (EPO) 10.14.4. Interferons 10.14.5. Growth Hormones 10.14.6. Fertility Hormones 10.15. Mexico Biosimilar and Follow-on Biologics Market Forecast, By Application 10.15.1. Blood disorders 10.15.2. Oncology diseases 10.15.3. Growth hormone deficiencies 10.15.4. Others 10.16. North America Biosimilar and Follow-on Biologics Market Attractiveness Analysis 10.16.1. By Product Class 10.16.2. By Application 10.17. PEST Analysis 10.18. Key Trends 10.19. Key Developments 11. Europe Biosimilar and Follow-on Biologics Market Analysis 11.1. Key Findings 11.2. Europe Biosimilar and Follow-on Biologics Market Overview 11.3. Europe Biosimilar and Follow-on Biologics Market Value Share Analysis, By Product Class 11.4. Europe Biosimilar and Follow-on Biologics Market Forecast, By Product Class 11.4.1. Monoclonal Antibodies (Mabs) 11.4.2. Insulin 11.4.3. Erythropoietin (EPO) 11.4.4. Interferon’s 11.4.5. Growth Hormones 11.4.6. Fertility Hormones 11.5. Europe Biosimilar and Follow-on Biologics Market Value Share Analysis, By Application 11.6. Europe Biosimilar and Follow-on Biologics Market Forecast, By Application 11.6.1. Blood disorders 11.6.2. Oncology diseases 11.6.3. Growth hormone deficiencies 11.6.4. Others 11.7. Europe Biosimilar and Follow-on Biologics Market Value Share Analysis, By Country 11.8. Europe Biosimilar and Follow-on Biologics Market Forecast, By Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Sweden 11.8.7. CIS countries 11.8.8. Rest of Europe 11.9. Germany Biosimilar and Follow-on Biologics Market Forecast, By Product Class 11.9.1. Monoclonal Antibodies (Mabs) 11.9.2. Insulin 11.9.3. Erythropoietin (EPO) 11.9.4. Interferons 11.9.5. Growth Hormones 11.9.6. Fertility Hormones 11.10. Germany Biosimilar and Follow-on Biologics Market Forecast, By Application 11.10.1. Blood disorders 11.10.2. Oncology diseases 11.10.3. Growth hormone deficiencies 11.10.4. Others 11.11. U.K. Biosimilar and Follow-on Biologics Market Forecast, By Product Class 11.11.1. Monoclonal Antibodies (Mabs) 11.11.2. Insulin 11.11.3. Erythropoietin (EPO) 11.11.4. Interferons 11.11.5. Growth Hormones 11.11.6. Fertility Hormones 11.12. U.K. Biosimilar and Follow-on Biologics Market Forecast, By Application 11.12.1. Blood disorders 11.12.2. Oncology diseases 11.12.3. Growth hormone deficiencies 11.12.4. Others 11.13. France Biosimilar and Follow-on Biologics Market Forecast, By Product Class 11.13.1. Monoclonal Antibodies (Mabs) 11.13.2. Insulin 11.13.3. Erythropoietin (EPO) 11.13.4. Interferons 11.13.5. Growth Hormones 11.13.6. Fertility Hormones 11.14. France Biosimilar and Follow-on Biologics Market Forecast, By Application 11.14.1. Blood disorders 11.14.2. Oncology diseases 11.14.3. Growth hormone deficiencies 11.14.4. Others 11.15. Italy Biosimilar and Follow-on Biologics Market Forecast, By Product Class 11.15.1. Monoclonal Antibodies (Mabs) 11.15.2. Insulin 11.15.3. Erythropoietin (EPO) 11.15.4. Interferons 11.15.5. Growth Hormones 11.15.6. Fertility Hormones 11.16. Italy Biosimilar and Follow-on Biologics Market Forecast, By Application 11.16.1. Blood disorders 11.16.2. Oncology diseases 11.16.3. Growth hormone deficiencies 11.16.4. Others 11.17. Spain Biosimilar and Follow-on Biologics Market Forecast, By Product Class 11.17.1. Monoclonal Antibodies (Mabs) 11.17.2. Insulin 11.17.3. Erythropoietin (EPO) 11.17.4. Interferons 11.17.5. Growth Hormones 11.17.6. Fertility Hormones 11.18. Spain Biosimilar and Follow-on Biologics Market Forecast, By Application 11.18.1. Blood disorders 11.18.2. Oncology diseases 11.18.3. Growth hormone deficiencies 11.18.4. Others 11.19. Sweden Biosimilar and Follow-on Biologics Market Forecast, By Product Class 11.19.1. Monoclonal Antibodies (Mabs) 11.19.2. Insulin 11.19.3. Erythropoietin (EPO) 11.19.4. Interferons 11.19.5. Growth Hormones 11.19.6. Fertility Hormones 11.20. Sweden Biosimilar and Follow-on Biologics Market Forecast, By Application 11.20.1. Blood disorders 11.20.2. Oncology diseases 11.20.3. Growth hormone deficiencies 11.20.4. Others 11.21. CIS countries Biosimilar and Follow-on Biologics Market Forecast, By Product Class 11.21.1. Monoclonal Antibodies (Mabs) 11.21.2. Insulin 11.21.3. Erythropoietin (EPO) 11.21.4. Interferons 11.21.5. Growth Hormones 11.21.6. Fertility Hormones 11.22. CIS countries Biosimilar and Follow-on Biologics Market Forecast, By Application 11.22.1. Blood disorders 11.22.2. Oncology diseases 11.22.3. Growth hormone deficiencies 11.22.4. Others 11.23. Rest of Europe Biosimilar and Follow-on Biologics Market Forecast, By Product Class 11.23.1. Monoclonal Antibodies (Mabs) 11.23.2. Insulin 11.23.3. Erythropoietin (EPO) 11.23.4. Interferons 11.23.5. Growth Hormones 11.23.6. Fertility Hormones 11.24. Rest of Europe Biosimilar and Follow-on Biologics Market Forecast, By Application 11.24.1. Blood disorders 11.24.2. Oncology diseases 11.24.3. Growth hormone deficiencies 11.24.4. Others 11.25. Europe Biosimilar and Follow-on Biologics Market Attractiveness Analysis 11.25.1. By Application 11.25.2. By Product Class 11.26. PEST Analysis 11.27. Key Trends 11.28. Key Developments 12. Asia Pacific Biosimilar and Follow-on Biologics Market Analysis 12.1. Key Findings 12.2. Asia Pacific Biosimilar and Follow-on Biologics Market Overview 12.3. Asia Pacific Biosimilar and Follow-on Biologics Market Value Share Analysis, By Product Class 12.4. Asia Pacific Biosimilar and Follow-on Biologics Market Forecast, By Product Class 12.4.1. Monoclonal Antibodies (Mabs) 12.4.2. Insulin 12.4.3. Erythropoietin (EPO) 12.4.4. Interferons 12.4.5. Growth Hormones 12.4.6. Fertility Hormones 12.5. Asia Pacific Biosimilar and Follow-on Biologics Market Value Share Analysis, By Application 12.6. Asia Pacific Biosimilar and Follow-on Biologics Market Forecast, By Application 12.6.1. Blood disorders 12.6.2. Oncology diseases 12.6.3. Growth hormone deficiencies 12.6.4. Others 12.7. Asia Pacific Biosimilar and Follow-on Biologics Market Value Share Analysis, By Country 12.8. Asia Pacific Biosimilar and Follow-on Biologics Market Forecast, By Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. South Korea 12.8.5. Australia 12.8.6. ASEAN 12.8.7. Rest of Asia Pacific 12.9. Asia Pacific Biosimilar and Follow-on Biologics Market Analysis, By Country 12.10. China Biosimilar and Follow-on Biologics Market Forecast, By Product Class 12.10.1. Monoclonal Antibodies (Mabs) 12.10.2. Insulin 12.10.3. Erythropoietin (EPO) 12.10.4. Interferons 12.10.5. Growth Hormones 12.10.6. Fertility Hormones 12.11. China Biosimilar and Follow-on Biologics Market Forecast, By Application 12.11.1. Blood disorders 12.11.2. Oncology diseases 12.11.3. Growth hormone deficiencies 12.11.4. Others 12.12. India Biosimilar and Follow-on Biologics Market Forecast, By Product Class 12.12.1. Monoclonal Antibodies (Mabs) 12.12.2. Insulin 12.12.3. Erythropoietin (EPO) 12.12.4. Interferons 12.12.5. Growth Hormones 12.12.6. Fertility Hormones 12.13. India Biosimilar and Follow-on Biologics Market Forecast, By Application 12.13.1. Blood disorders 12.13.2. Oncology diseases 12.13.3. Growth hormone deficiencies 12.13.4. Others 12.14. Japan Biosimilar and Follow-on Biologics Market Forecast, By Product Class 12.14.1. Monoclonal Antibodies (Mabs) 12.14.2. Insulin 12.14.3. Erythropoietin (EPO) 12.14.4. Interferons 12.14.5. Growth Hormones 12.14.6. Fertility Hormones 12.15. Japan Biosimilar and Follow-on Biologics Market Forecast, By Application 12.15.1. Blood disorders 12.15.2. Oncology diseases 12.15.3. Growth hormone deficiencies 12.15.4. Others 12.16. South Korea Biosimilar and Follow-on Biologics Market Forecast, By Product Class 12.16.1. Monoclonal Antibodies (Mabs) 12.16.2. Insulin 12.16.3. Erythropoietin (EPO) 12.16.4. Interferons 12.16.5. Growth Hormones 12.16.6. Fertility Hormones 12.17. South Korea Biosimilar and Follow-on Biologics Market Forecast, By Application 12.17.1. Blood disorders 12.17.2. Oncology diseases 12.17.3. Growth hormone deficiencies 12.17.4. Others 12.18. Australia Biosimilar and Follow-on Biologics Market Forecast, By Product Class 12.18.1. Monoclonal Antibodies (Mabs) 12.18.2. Insulin 12.18.3. Erythropoietin (EPO) 12.18.4. Interferons 12.18.5. Growth Hormones 12.18.6. Fertility Hormones 12.19. Australia Biosimilar and Follow-on Biologics Market Forecast, By Application 12.19.1. Blood disorders 12.19.2. Oncology diseases 12.19.3. Growth hormone deficiencies 12.19.4. Others 12.20. ASEAN Biosimilar and Follow-on Biologics Market Forecast, By Product Class 12.20.1. Monoclonal Antibodies (Mabs) 12.20.2. Insulin 12.20.3. Erythropoietin (EPO) 12.20.4. Interferons 12.20.5. Growth Hormones 12.20.6. Fertility Hormones 12.21. ASEAN Biosimilar and Follow-on Biologics Market Forecast, By Application 12.21.1. Blood disorders 12.21.2. Oncology diseases 12.21.3. Growth hormone deficiencies 12.21.4. Others 12.22. Rest of Asia Pacific Biosimilar and Follow-on Biologics Market Forecast, By Product Class 12.22.1. Monoclonal Antibodies (Mabs) 12.22.2. Insulin 12.22.3. Erythropoietin (EPO) 12.22.4. Interferons 12.22.5. Growth Hormones 12.22.6. Fertility Hormones 12.23. Rest of Asia Pacific Biosimilar and Follow-on Biologics Market Forecast, By Application 12.23.1. Blood disorders 12.23.2. Oncology diseases 12.23.3. Growth hormone deficiencies 12.23.4. Others 12.24. Asia Pacific Biosimilar and Follow-on Biologics Market Attractiveness Analysis 12.24.1. By Product Class 12.24.2. By Application 12.25. PEST Analysis 12.26. Key Trends 12.27. Key Developments 13. Middle East & Africa Biosimilar and Follow-on Biologics Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Biosimilar and Follow-on Biologics Market Overview 13.3. Middle East & Africa Biosimilar and Follow-on Biologics Market Value Share Analysis, By Product Class 13.4. Middle East & Africa Biosimilar and Follow-on Biologics Market Forecast, By Product Class 13.4.1. Monoclonal Antibodies (Mabs) 13.4.2. Insulin 13.4.3. Erythropoietin (EPO) 13.4.4. Interferons 13.4.5. Growth Hormones 13.4.6. Fertility Hormones 13.5. Middle East & Africa Biosimilar and Follow-on Biologics Market Value Share Analysis, By Application 13.6. Middle East & Africa Biosimilar and Follow-on Biologics Market Forecast, By Application 13.6.1. Blood disorders 13.6.2. Oncology diseases 13.6.3. Growth hormone deficiencies 13.6.4. Others 13.7. Middle East & Africa Biosimilar and Follow-on Biologics Market Value Share Analysis, By Country 13.8. Middle East & Africa Biosimilar and Follow-on Biologics Market Forecast, By Country 13.8.1. GCC Countries 13.8.2. South Africa 13.8.3. Nigeria 13.8.4. Egypt 13.8.5. Rest of Middle East & Africa 13.9. Middle East & Africa Biosimilar and Follow-on Biologics Market Analysis, By Country 13.10. GCC Countries Biosimilar and Follow-on Biologics Market Forecast, By Product Class 13.10.1. Monoclonal Antibodies (Mabs) 13.10.2. Insulin 13.10.3. Erythropoietin (EPO) 13.10.4. Interferons 13.10.5. Growth Hormones 13.10.6. Fertility Hormones 13.11. GCC Countries Biosimilar and Follow-on Biologics Market Forecast, By Application 13.11.1. Blood disorders 13.11.2. Oncology diseases 13.11.3. Growth hormone deficiencies 13.11.4. Others 13.12. South Africa Biosimilar and Follow-on Biologics Market Forecast, By Product Class 13.12.1. Monoclonal Antibodies (Mabs) 13.12.2. Insulin 13.12.3. Erythropoietin (EPO) 13.12.4. Interferons 13.12.5. Growth Hormones 13.12.6. Fertility Hormones 13.13. South Africa Biosimilar and Follow-on Biologics Market Forecast, By Application 13.13.1. Blood disorders 13.13.2. Oncology diseases 13.13.3. Growth hormone deficiencies 13.13.4. Others 13.14. Nigeria Biosimilar and Follow-on Biologics Market Forecast, By Product Class 13.14.1. Monoclonal Antibodies (Mabs) 13.14.2. Insulin 13.14.3. Erythropoietin (EPO) 13.14.4. Interferons 13.14.5. Growth Hormones 13.14.6. Fertility Hormones 13.15. Nigeria Biosimilar and Follow-on Biologics Market Forecast, By Application 13.15.1. Blood disorders 13.15.2. Oncology diseases 13.15.3. Growth hormone deficiencies 13.15.4. Others 13.16. Egypt Biosimilar and Follow-on Biologics Market Forecast, By Product Class 13.16.1. Monoclonal Antibodies (Mabs) 13.16.2. Insulin 13.16.3. Erythropoietin (EPO) 13.16.4. Interferons 13.16.5. Growth Hormones 13.16.6. Fertility Hormones 13.17. Egypt Biosimilar and Follow-on Biologics Market Forecast, By Application 13.17.1. Blood disorders 13.17.2. Oncology diseases 13.17.3. Growth hormone deficiencies 13.17.4. Others 13.18. Rest of Middle East & Africa Biosimilar and Follow-on Biologics Market Forecast, By Product Class 13.18.1. Monoclonal Antibodies (Mabs) 13.18.2. Insulin 13.18.3. Erythropoietin (EPO) 13.18.4. Interferons 13.18.5. Growth Hormones 13.18.6. Fertility Hormones 13.19. Rest of Middle East & Africa Biosimilar and Follow-on Biologics Market Forecast, By Application 13.19.1. Blood disorders 13.19.2. Oncology diseases 13.19.3. Growth hormone deficiencies 13.19.4. Others 13.20. Middle East & Africa Biosimilar and Follow-on Biologics Market Attractiveness Analysis 13.20.1. By Product Class 13.20.2. By Application 13.21. PEST Analysis 13.22. Key Trends 13.23. Key Developments 14. South America Biosimilar and Follow-on Biologics Market Analysis 14.1. Key Findings 14.2. South America Biosimilar and Follow-on Biologics Market Overview 14.3. South America Biosimilar and Follow-on Biologics Market Value Share Analysis, By Product Class 14.4. South America Biosimilar and Follow-on Biologics Market Forecast, By Product Class 14.4.1. Monoclonal Antibodies (Mabs) 14.4.2. Insulin 14.4.3. Erythropoietin (EPO) 14.4.4. Interferons 14.4.5. Growth Hormones 14.4.6. Fertility Hormones 14.5. South America Biosimilar and Follow-on Biologics Market Value Share Analysis, By Application 14.6. South America Biosimilar and Follow-on Biologics Market Forecast, By Application 14.6.1. Blood disorders 14.6.2. Oncology diseases 14.6.3. Growth hormone deficiencies 14.6.4. Others 14.7. South America Biosimilar and Follow-on Biologics Market Value Share Analysis, By Country 14.8. South America Biosimilar and Follow-on Biologics Market Forecast, By Country 14.8.1. Brazil 14.8.2. Colombia 14.8.3. Argentina 14.8.4. Rest of South America 14.9. South America Biosimilar and Follow-on Biologics Market Analysis, By Country 14.10. Brazil Biosimilar and Follow-on Biologics Market Forecast, By Product Class 14.10.1. Monoclonal Antibodies (Mabs) 14.10.2. Insulin 14.10.3. Erythropoietin (EPO) 14.10.4. Interferons 14.10.5. Growth Hormones 14.10.6. Fertility Hormones 14.11. Brazil Biosimilar and Follow-on Biologics Market Forecast, By Application 14.11.1. Blood disorders 14.11.2. Oncology diseases 14.11.3. Growth hormone deficiencies 14.11.4. Others 14.12. Colombia Biosimilar and Follow-on Biologics Market Forecast, By Product Class 14.12.1. Monoclonal Antibodies (Mabs) 14.12.2. Insulin 14.12.3. Erythropoietin (EPO) 14.12.4. Interferons 14.12.5. Growth Hormones 14.12.6. Fertility Hormones 14.13. Colombia Biosimilar and Follow-on Biologics Market Forecast, By Application 14.13.1. Blood disorders 14.13.2. Oncology diseases 14.13.3. Growth hormone deficiencies 14.13.4. Others 14.14. Argentina Biosimilar and Follow-on Biologics Market Forecast, By Product Class 14.14.1. Monoclonal Antibodies (Mabs) 14.14.2. Insulin 14.14.3. Erythropoietin (EPO) 14.14.4. Interferons 14.14.5. Growth Hormones 14.14.6. Fertility Hormones 14.15. Argentina Biosimilar and Follow-on Biologics Market Forecast, By Application 14.15.1. Blood disorders 14.15.2. Oncology diseases 14.15.3. Growth hormone deficiencies 14.15.4. Others 14.16. Rest of South America Biosimilar and Follow-on Biologics Market Forecast, By Product Class 14.16.1. Monoclonal Antibodies (Mabs) 14.16.2. Insulin 14.16.3. Erythropoietin (EPO) 14.16.4. Interferons 14.16.5. Growth Hormones 14.16.6. Fertility Hormones 14.17. Rest of South America Biosimilar and Follow-on Biologics Market Forecast, By Application 14.17.1. Blood disorders 14.17.2. Oncology diseases 14.17.3. Growth hormone deficiencies 14.17.4. Others 14.18. South America Biosimilar and Follow-on Biologics Market Attractiveness Analysis 14.18.1. By Product Class 14.18.2. By Application 14.19. PEST Analysis 14.20. Key Trends 14.21. Key Developments 15. Company Profiles 15.1. Market Share Analysis, By Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players By price, presence, market share, Component, and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A By Regions, Investment and Component 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Zydus Cadila 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Development Footprint 15.3.2. Dr. Reddy's Laboratories 15.3.3. Emcure Pharmaceuticals 15.3.4. Wockhardt 15.3.5. Roche 15.3.6. Quintiles 15.3.7. Gennova 15.3.8. Bayer 15.3.9. AstraZeneca 15.3.10. Hindustan Antibiotic 15.3.11. Takeda 15.3.12. GlaxoSmithKline 15.3.13. Teva 15.3.14. Syngene International 15.3.15. Pfizer 15.3.16. Johnson & Johnson 15.3.17. Ortho Pharmaceutical 15.3.18. Sanofi 15.3.19. Merck KGaA 15.3.20. Samsung BioLogics 15.3.21. Ranbaxy Laboratories 15.3.22. Novartis 15.3.23. Novo Nordisk 16. Primary key Insights

About This Report

Report ID 83592
Category Healthcare
Published Date February 2021
No of Pages 186
Contact Us